Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.24 +0.04 (+0.25%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sarepta: More Drama Or Just More Noise?
Sarepta has a history at the FDA and recent reports indicate additional issues. What are the implications for accelerated approval and the long term prospects of Sarepta? 
Via Talk Markets
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know
Via Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness
Via Benzinga
FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy
Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy. 
Via Benzinga
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
According to a report, some staffers wanted to reject the highly watched drug. 
Via Investor's Business Daily
Why Is Merck (MRK) Stock Up Today?
Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda. 
Via InvestorPlace
Why Is BigBear.ai (BBAI) Stock Down 5% Today?
BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. 
Via InvestorPlace
Why Sarepta Therapeutics Stock Is Tumbling Today
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shareholder Notice: Investigation over Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 04/10/2023 -- Sarepta Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
From Sarepta Therapeutics, Inc.
Via Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
2 Top Growth Stocks That Could Soar This Spring
Exciting news on the way for both of these companies could send their stock prices screaming higher. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
3 Up-and-Coming Growth Stocks to Buy Right Now
These companies are small now but could grow much larger over time. 
Via The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process
The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood... 
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS